

The Role of the Hemostasis and Thrombosis Unit in the Management of the Patients with Acquired Hemophilia

Antonella Mamei¹, Francesco Marongiu², Lara Fenu¹, Maria Filomena Ruberto³, Paola Schirru¹, Simona Cornacchini¹, Doris Barcellona⁴

¹Azienda Ospedaliero-Universitaria di Cagliari Dipartimento di Medicina Cagliari, Italy

²University of Cagliari Faculty of Sciences, Monserrato, Sardegna, Italy

³Casa Di Cura Madonna del Rimedio, Oristano, Italy

⁴University of Cagliari - Medical Science and Public Health Viale Roberto Sequi Monserrato (CA), Cagliari 09124 Italy

Doris Barcellona M.D., University of Cagliari - Medical Science and Public Health Viale Roberto Sequi Monserrato (CA), Cagliari 09124 Italy

0706754188

doris.barcellona@unica.it

June 23, 2024

October 24, 2024

Abstract:

Objective: Acquired hemophilia A (AHA) is a rare autoimmune disease characterised by the presence of autoantibodies against coagulation factor VIII (FVIII), leading to spontaneous haemorrhage in patients without a prior family or personal history of bleeding. This study describes the demographics, diagnosis, underlying disorders, bleeding characteristics, treatment, and outcomes of 41 AHA patients, along with specific case reports.

Materials and Methods: Diagnosis and treatment occurred between 2005 and 2023. The median age at diagnosis was 67.8 years (range 15–93). Among the 41 patients, 10 (24%) were idiopathic, 4 (10%) were postpartum, 18 (44%) had autoimmune diseases, and 9 were diagnosed with cancer.

Results: Diagnostic delay exceeded 30 days in 15 out of the 41 cases (36.5%). A total of 38 out of the 41 (93%) patients presented with spontaneous bleeding, with mucocutaneous bleeding being the most common presentation (23/41, 56%). Four patients experienced postpartum bleeding. Clinical remission was achieved in 100% of patients, and no patient died.

Conclusion: Haemostatic and Immunosuppressive therapy is essential in AHA, and it should be started as soon as possible in patients with bleeding. However, a significant delay in diagnosis was observed. The absence of mortality is likely attributable to the management of the disease within a specialised Haemostasis and Thrombosis Unit, which offers a clinical ward, a specialised laboratory, and a dedicated ambulatory service. The Italian Society for the Study of Haemostasis and Thrombosis (SISST) is working to secure recognition for this essential role in every hospital.

Keywords: Acquired haemophilia A, Factor VIII inhibitors, bleeding, bypassing agents, inhibitor eradication

Introduction

Acquired haemophilia A (AHA) is a rare autoimmune disease with an estimated incidence of 1.34–1.48 per million per year [1]. The incidence increases with age, being particularly uncommon in children, where it is estimated at 0.045 per million per year, compared to 14.7 per million per year in individuals over 85 years [2]. The age distribution of autoantibodies is typically biphasic with a minor peak between 20 and 30 years due to postpartum inhibitors, and a major peak in patients aged 68 to 80 years. The distribution of AHA in men and women is similar, except in the 20 to 40-year age range, where pregnancy has a significant impact [3]. In approximately 50% of cases, Factor VIII (FVIII) autoantibodies occur in patients without any identifiable concomitant disease, while the remaining cases may be associated with the postpartum period, autoimmune diseases, underlying hematologic or solid cancers, infections, or medication use [4]. Bleeding manifestations can occur at various sites – either spontaneously or following trauma or invasive procedures – and vary greatly in severity, sometimes being life-threatening. The bleeding is typically

mucocutaneous, involving soft tissue, muscles, the gastrointestinal tract, and the urogenital system, rather than hemarthrosis, which is more common in congenital haemophilia [5]. AHA is characterised by the development of antibodies against coagulation factors, primarily Factor VIII. These autoantibodies (IgG1 and IgG4) are polyclonal and target epitopes in domains A2, A3, and C2 of the FVIII molecule, interfering with factor IX (FIX), phospholipids, and von Willebrand factor (VWF) [6]. The onset of the disease can be dramatic, exposing patients to haemorrhagic shock or severe bleeding, with a mortality risk ranging from 3% to 9% [7,8]. However, in about 30% of patients, bleeding is mild and does not necessitate haemostatic treatment [5]. AHA is suspected in patients with unprovoked bleeding, a negative personal and family history of haemorrhages, and a prolonged aPTT that is not corrected after a mixing test with normal plasma. A low FVIII level and the presence of FVIII inhibitor titres, confirmed by the Nijmegen-Bethesda method, establish the diagnosis [9]. AHA is often unrecognised, exposing patients to a higher risk of death due to the prolonged time between the onset of bleeding and correct diagnosis and treatment. This study analyses and discusses the clinical and laboratory data, treatment, outcomes, and long-term follow-ups of 41 AHA patients diagnosed in our Haemostasis and Thrombosis Unit. between 2005 and 2023. Treatment decisions were tailored to the severity of bleeding, and all patients were monitored in long-term follow-ups to document treatment success, relapse, or death from any cause. Additionally, specific cases are presented and discussed.

Patients and Methods

Between 2005 and 2023, 41 AHA cases were diagnosed in a Haemostasis and Thrombosis Departmental Unit (HTDU). All 41 patients identified in this study were adults. The population of Sardinia was 1,575,028 in 2023, with South Sardinia having 753,000 and Central Sardinia 348,000 (Istat January 1, 2023). For our study population in South and Central Sardinia (41 cases), the estimated incidence of AHA is 2 cases per million per year (ranging from 0.9 to 5.4 cases per million). In 2016, 2018, and 2023, a relatively high number of patients (6, 5, and 6 cases, respectively) were diagnosed (Figure 1).

The median age at diagnosis was 67.8 years (range 15–93).

All patients in this series were admitted to our Unit's clinical ward. Electronic registration forms captured data on age at diagnosis, sex, clinical manifestations, type of bleeding at diagnosis, duration of diagnostic delay, laboratory results, and the haemostatic and immunosuppressive treatment approach. Follow-up was conducted in the ambulatory section of the Unit. Coagulation screening tests, including prothrombin time (recombinant thromboplastin Werfen, Spain), APTT (silica-based, Werfen), factor VIII one-stage assay, and inhibitor assay using the Bethesda method, were performed in the laboratory of the HTDU. A mixing study was conducted to demonstrate the presence of inhibitors prior to the factor VIII coagulant and inhibitor assays. All patients were admitted to the HTDU ward. Hospitalisation required each patient to accept the protocol outlined by law 196/2003 (personal data treatment). This protocol informed patients that their sensitive data would be treated anonymously and could be used for scientific purposes (e.g. in scientific publications) and/or educational presentations during congresses, symposia, conferences, lectures, refresher courses, and any scientific and educational discussions with medical and healthcare personnel (including lessons for medical and nursing students). All statistical analyses were performed using MedCalc software (version 14.8.1, MedCalc Software, Ostend, Belgium). As this is a retrospective study and all patients were treated according to international guidelines, exemption from the Ethical Committee was appropriate.

Results

All the results are summarized in the Table 1.

Demographic and coagulation profile

Our group consisted of 19 men and 22 women, indicating an approximately equivalent incidence in both sexes. The median age at diagnosis was 67.8 years (range 15–93). There was no significant correlation between FVIII inhibitor titre and FVIII level (correlation coefficient, $r=0.4$, $p=0.9$).

Etiology

Ten out of the 41 patients (24%) had no identifiable underlying etiology for the inhibitor (i.e. they were idiopathic), 4 (10%) were postpartum, 18 (44%) had autoimmune diseases (including Rheumatic Polymyalgia, Rheumatoid Arthritis, Sjogren Syndrome, Celiac disease, and Systemic Lupus Erythematosus), while 9 patients were diagnosed with cancer.

Clinical presentations and haemostatic treatment

The median time from the first bleeding episode to diagnosis (diagnostic delay) was more than 30 days in 15 out of the 41 cases (36.5%), between 7 and 30 days in 22 cases (54%), while only 4 (10%) received a diagnosis within the first week of bleeding onset. All patients presented with active bleeding at diagnosis, with spontaneous bleeding in 38 out of the 41 cases (93%). The most common presentation was mucocutaneous bleeding (23/41, 56%), followed by muscle haematoma (25/41, 61%). One patient presented with compartment syndrome, and two patients with muscle hematoma were initially mismanaged as deep venous thrombosis. Gastrointestinal bleeding and hemarthrosis were uncommon. Three patients had haemorrhagic bullae. Four patients experienced postpartum bleeding. In one (2.4%) patient, we observed femoral-popliteal vein thrombosis during the first seven days of hospitalisation, while the FVIII:C was 3%.

Management of bleeding

Management of bleeding in AHA depended on the type and severity of the bleeding. To arrest acute bleeding, patients were treated with one or more of the following agents: activated prothrombin complex concentrate (APCC) (FEIBA; Baxter Immuno AG, Vienna, Austria) and recombinant human activated factor VII (rFVIIa) (NovoSeven; Novo Nordisk A/S, Bagsvaerd, Denmark). Acute bleeding was defined as new onset bleeding requiring treatment, while severe bleeding was defined as bleeding from visceral organs or the retroperitoneal compartment, or as life-threatening bleeding. Haemostatic parameters, by-pass agents and Immunosuppressive therapies are reported in. Other haemostatic agents included fresh frozen plasma (FFP), which was used in two patients before a correct diagnosis was made. Tranexamic acid was also used for mucocutaneous bleeding and as adjunctive haemostatic treatment in all patients. Seven (17%) patients received more than one type of haemostatic agent.

Six out of the 41 patients (16%) were using antiplatelet drugs due to a personal history of arterial ischaemic events, particularly coronary artery disease. Atrial fibrillation was documented in one patient on anticoagulant therapy (Dabigatran). Once FVIII:C levels recovered (>30%), primary or secondary antithrombotic prophylaxis was restarted if the criteria for anticoagulation or antiplatelet therapy were still met.

Steroids were the most frequently used immunosuppressive agent, particularly in combination with cyclophosphamide. Rituximab, in conjunction with other immunosuppressive agents, including steroids, was the second choice for two patients. Five (12%) patients who did not respond to a combination of steroids and cyclophosphamide were treated with immunoglobulins; three (7%) patients received plasmapheresis; and one (2.4%) patient received methotrexate.

Clinical remission (CR) was achieved in 41 out of 41 (100%) patients. No patient died during hospitalisation. Two patients died one month after discharge due to neoplastic disease, and one patient died 20 days after discharge due to infectious complications.

Furthermore, we observed only one relapse a year later after complete remission in a patient with an autoimmune disease (Rheumatic Polymyalgia).

Discussion

This paper presents our case series managed according to the international guidelines available in the literature [10,11]. All aspects related to the diagnostic approach and the haemostatic and immunosuppressive treatment were appropriately addressed [12]. It is worth noting that Immunosuppressive therapy is essential in AHA, and it should be started as soon as possible in patients with bleeding. Our results align closely with those published on factor VIII levels, bleeding characteristics, and inhibitor levels. However, we observed some differences upon comparison with data from the largest registry on the disease [13]. Our percentage of idiopathic AHA is significantly lower (24%) than that of the Registry (51%). Similarly, the incidence of thrombotic events is lower in our data: 2.4% (1 out of 41) versus 4.8% in the Registry. No drug-induced AHA was present in our series, and no patient died. The incidence of AHA was higher in our series compared to general data reported, attributable to the genetic characteristics of Sardinia, where the incidence of autoimmune diseases is relatively high [14]. The complex genetic landscape of Sardinia may stem from malaria, which was endemic until the 1950s, favouring the selection of genetic variants that mitigate disease severity, such as G6PD deficiency and Thalassemia traits. However, other variants have been selected that confer a propensity for autoimmune diseases such as Type 1 Diabetes, Multiple Sclerosis, and Autoimmune Thyroiditis [15]. Our series clearly demonstrated a delay in diagnosis of AHA, with nearly 40% of patients experiencing a delay of over 30 days from the onset of the disease to the final diagnosis. This delay may occur because AHA is rare and often overlooked by both general and specialised physicians. Additionally, there is a disconnect in linking a major haemorrhagic event with a prolonged aPTT, which is frequently disregarded. Another concern is that many general laboratories do not perform the aPTT mixing test, significantly limiting an accurate diagnostic approach. These issues have been well documented by Pardos-Gea et al., who described the causes of diagnostic delay in their 20-year experience [16]. They also reported instances where calf swelling without external signs of haemorrhage was misinterpreted as deep vein thrombosis, leading to the use of low molecular weight heparin (LMWH) and resulting in a worse bleeding scenario. This occurred in two of our patients. In one case, a compressive muscle haematoma developed in both arms, resulting in a compartment syndrome characterised by an ischaemic clinical picture that necessitated surgery. Surgery was associated with a significantly worse bleeding scenario, requiring much larger quantities of activated factor VII. We propose two figures illustrating the main points for suspecting the presence of the disease, which could be disseminated among general practitioners to enhance awareness. Another notable aspect of this series is that no patient died before attaining complete remission. This outcome contrasts with literature reports indicating mortality rates between 3% and 9% [7]. We assert that this remarkable result was achieved because all patients received care within the same specialised ward of the ETDU, where the personnel were consistently specialised in the field of Haemostasis and Thrombotic diseases within an Internal Medicine department. Additionally, the Unit includes a specialised laboratory. We believe that an internist approach to the disease has played a favourable role, facilitating the management of the adverse effects of various therapies and the frequent underlying conditions associated with AHA. Interestingly, we observed that activated factor VII was used more frequently than aPCC. However, it is worth noting that both bypass agents have been found to yield similar results in controlling bleeding, allowing for the use of either agent [17]. We would like to briefly describe and comment on three patients from this series. The first was a patient with a very low factor VIII level (~0%) and a very high inhibitor level (229 BU), which was reduced to 28 BU by plasmapheresis. This patient was treated with immunosuppressive and bypass agents, but factor VIII levels remained near 0% for several weeks, despite the absence of overt bleeding. Given

the high risk of bleeding, we decided to introduce emicizumab, a monoclonal bispecific antibody that bridges both factor IX and X, mimicking factor VIII activity [18]. The results were optimal, with factor VIII levels rising to 11% without any bleeding during the second weekly administration of this drug. However, the use of emicizumab is off-label in AHA. Nevertheless, several studies have demonstrated its efficacy and safety in these patients [19,20]. The second patient developed mantle cell lymphoma after a year and a half of complete remission. The neoplastic disease was suspected during follow-up and confirmed by lymph node biopsy. Complete remission was achieved following chemotherapy and autologous and allogenic bone marrow transplantation [21]. Other cases of malignant lymphoma following AHA have been documented in the literature [22], suggesting that long-term follow-up is advisable for these patients. The third case involved a 66-year-old woman who was a Jehovah's Witness. She was admitted to our Internal Medicine with a large haematoma in her left thigh, ecchymosis, and another large haematoma in her right shoulder. She had a history of Sjogren syndrome and Type 2 Diabetes. Laboratory parameters indicated a prolonged aPTT (factor VIII: 4.4%) and a haemoglobin level of 6 g/dl. She also had severe renal failure (MDRD 28 ml/min). Although management of bleeding with bypass agents and the immunosuppressive treatment commenced immediately, treating her anaemia proved challenging due to her refusal of blood transfusions [23]. Our approach involved infusions of saline and gelatin-colloid solutions, along with intravenous iron and erythropoietin. Her haemoglobin fell to 4.0 g/dl, coinciding with an increase in creatinine levels (4.97 mg/dl for an MDRD value of 9 ml/min). Nevertheless, she was discharged after sixteen days, having attained complete remission (aPTT within the normal range without any new bleeding), improved haemoglobin levels (7.5 g/dl), and an MDRD of 24.1. Her haemodynamic condition was stable. Days after discharge, her haemoglobin level increased to 9.8 g/dl, and her MDRD value remained stable. She was followed for two years, during which no relapse was observed.

This study has some limitations that warrant discussion. It is a retrospective single-centre study, albeit covering 18 years and including a relatively large cohort of 41 patients. We emphasise that single-centre studies, while limited, can provide valuable insights into local medical approaches, thereby enhancing experience in a specific field. Local studies should be encouraged without undermining the importance of establishing large registries dedicated to rare diseases such as AHA. Another limitation is the non-use of Recombinant porcine Factor VIII (Obizur), which could have been beneficial for more critical patients [24,25]. However, in our series, bleeding was effectively managed, as evidenced by the absence of mortality. Another reason for not using this treatment was the lack of round-the-clock laboratory availability for measuring factor VIII activity to administer appropriate drug doses.

Conclusions

This study demonstrates that a single specialised Centre in Haemostasis and Thrombosis can effectively manage patients with AHA. We observed a significant delay in diagnosis by non-specialised or general practitioners, who often overlook the disease and the fundamental principles of the haemostatic system. This issue could be mitigated by disseminating educational materials in a straightforward format to facilitate the recognition of AHA. We emphasise that no patient died because the management of the disease was conducted in a specialised unit equipped with a clinical ward, a specialised laboratory, and a dedicated ambulatory service. This is crucial for optimal patient care. Furthermore, we believe that having an expert in Haemostasis and Thrombosis is essential. Several patients in our series were referred to our Unit from other hospitals lacking experience in managing the disease. The Italian Society for the Study of Haemostasis and Thrombosis (SISST) is working to secure recognition for this essential role in every hospital.

Word count excluding abstract: 2633

Author Contributions

Conceptualisation: M.A., F.M.; data curation: M.R. and L.F.; writing—original draft preparation: M.A. and F.M.; literature search: S.P. and S.A.C.; supervision: D.B.; writing—review and editing: F.M. All authors have read and agreed to the published version of the manuscript.

References

1. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. *Blood*. 2007;109:1870-1877.
2. Moraca RJ, Ragni MV. Acquired Anti-FVIII Inhibitors in Children. *Haemophilia*. 2002;8:28-32.
3. Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired Hemophilia A: A Concise Review. *Am J Hematol*. 2005;80:55-63.
4. Zanon, E. Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment. *Diagnostics (Basel)*. 2023;13:420.
5. Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Nemes L, Pellegrini F, Tengborn L, Knoebl P; EACH2 registry contributors. Management of Bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. *Blood*. 2012;120:39-46.
6. Goodeve AC, Rosén S, Verbruggen, B. Haemophilia A and von Willebrand's Disease. *Haemophilia*. 2010;16

- (Suppl 5):79–84.
7. Marino R. Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies. *Medicina (Kaunas)*. 2023;59:1739.
 8. Franchini M, Vaglio S, Marano G, Mengoli C, Gentili S, Pupella S, Liumbruno GM. Acquired hemophilia A: a review of recent data and new therapeutic options. *Hematology*. 2017;22:514-520.
 9. Coppola A, Favalaro EJ, Tufano A, Di Minno MND, Cerbone AM, Franchini M. Acquired Inhibitors of Coagulation Factors: Part I-Acquired Hemophilia A. *Semin Thromb Hemost*. 2012; 38:433–446.
 10. Coppola A, Franchini M, Tripodi A, Santoro RC, Castaman G, Marino R, Zanon E, Santoro C, Rivolta GF, Contino L, De Cristofaro R, Molinari AC, Gresele P, Rocino A; ad hoc Working Group (Appendix 1). Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. *Blood Transfus*. 2022;20:245-262.
 11. Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, Castellano ME, Shima M, St-Louis J. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. *Haematologica*. 2009;94:566-575.
 12. Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M, Di Minno G, d'Oiron R, Salaj P, Jiménez-Yuste V, Huth-Kühne A, Giangrande P. International recommendations on the diagnosis and treatment of acquired hemophilia A. *Haematologica*. 2020;105:1791-1801.
 13. Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, Pellegrini F, Tengborn L, Lévesque H; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). *J Thromb Haemost*. 2012;10:622-631.
 14. Orrù V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, Sole G, Lai S, Dei M, Mulas A, Virdis F, Piras MG, Lobina M, Marongiu M, Pitzalis M, Deidda F, Loizedda A, Onano S, Zoledziewska M, Sawcer S, Devoto M, Gorospe M, Abecasis GR, Floris M, Pala M, Schlessinger D, Fiorillo E, Cucca F. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. *Nat Genet*. 2020;52:1036-1045.
 15. Paladini F, Fiorillo MT, Tedeschi V, Cauli A, Mathieu A, Sorrentino R. Ankylosing Spondylitis: A Trade Off of HLA-B27, ERAP, and Pathogen Interconnections? Focus on Sardinia. *Front Immunol*. 2019;10:35.
 16. Pardos-Gea J, Fernández-Díaz N, Parra R, Cortina V, Altisent C. Diagnostic Delay in Acquired Haemophilia: Analysis of Causes and Consequences in a 20-Year Spanish Cohort. *Haemophilia*. 2018;24:e163–e166.
 17. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E; FENOC Study Group. A randomised comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. *Blood*. 2007;109:546-551.
 18. Mahlangu J, Iorio A, Kenet G. Emicizumab State-of-the-Art Update. *Haemophilia*. 2022;28 (Suppl 4):103–110.
 19. Engelen MM, Vandesande J, De Bent J, Van Laer C, Labarque V, Jacquemin M, Peerlinck K, Hermans C, Verhamme P, Vanassche T. Emicizumab for acquired haemophilia A: A case series. *Haemophilia*. 2023;29:1049-1055.
 20. Pasca S, Zanon E, Mannucci PM, Peyvandi F. Emicizumab in Acquired Hemophilia A: Pros and Cons of a New Approach to the Prevention and Treatment of Bleeding. *Blood Transfus*. 2023;21: 549–556.
 21. Porru M, Mameli A, Cianchetti EM, Musu M, Montisci R, Finco G, Marongiu F. Acquired factor VIII inhibitor and subsequent development of non-Hodgkin's lymphoma: a case report and review of the literature. *Blood Coagul Fibrinolysis*. 2015;26:967-971.
 22. de Vitry A, Valois A, Weinborn M, Dupuy-de Fonclare AL, Cuny JF, Barbaud A, Schmutz JL. Deux observations d'hémophilie A acquise [Acquired haemophilia A: two cases]. *Ann Dermatol Venereol*. 2014;141:441-445. French.
 23. Posluszny JAJ, Napolitano LM. How Do We Treat Life-Threatening Anemia in a Jehovah's Witness Patient? *Transfusion*. 2014;54:3026–3034.
 24. Campbell S, Mason J, Prasad R, Ambrose H, Hunt S, Tran H. Acquired Haemophilia and Haemostatic Control with Recombinant Porcine Factor VIII: Case Series. *Intern Med J*. 2021;51: 215–219.
 25. Zanon E, Pasca S, Borchiellini A, Lodigiani C, Molinari AC, Ambaglio C, et al. Susoctocog-Alfa (Obizur®) in the Treatment of Nine Elderly Patients with Acquired Haemophilia A: An Italian Multicentre Real World Experience. *Blood Transfus*. 2020; 18: 312–321.

Table 1. Characteristic of the patients with AHA									
No	Sex	Year of diagnosis	Age yr	aPT T, s	FVII I IU/dl	Inhibitor, BU/ml	DD (days)	Hemostasis management	Immunosuppressive therapy
1	F	2005	59	125	0.5	150	24	RFVIIa, TXA, FFP	Prednisone, CP, CsA, RTX, IVIG, PEX
2	F	2005	15	97	1	29.6	72	RFVIIa, TXA	Prednisone, CP
3	F	2006	39	82	1	12	57	RFVIIa, TXA	Prednisone, CP
4	F	2008	81	87	0.7	48	16	APCC, TXA	Prednisone, CP
5	M	2009	45	130	0.2	20	99	RFVIIa, TXA, FFP	Prednisone, CP, CsA, RXT, IVIG
6	M	2010	68	108	0.4	21	7	APCC, TXA	Prednisone, CsA
7	M	2011	82	110	0.1	17	10	APCC, TXA	Prednisone
8	M	2012	78	103	1.4	22	28	APCC, TXA	Prednisone, CP
9	M	2013	82	118	0.1	416	26	RFVIIa, aPCC, TXA	Prednisone, CP
10	F	2013	50	114	1	25.6	20	RFVIIa, TXA	Prednisone, CP
11	F	2013	34	108	0.6	17	34	RFVIIa, TXA	Prednisone, CP
12	M	2014	82	125	0.6	18	23	APCC, TXA	Prednisone, CP
13	F	2015	77	56	4	22.4	26	APCC, TXA	Prednisone, CP
14	M	2016	56	83	0.3	224	14	APCC, TXA	Prednisone, CP
15	F	2016	84	68	2	96	24	APCC, TXA	Prednisone, CP
16	F	2016	29	66	0.4	4	42	APCC, TXA	Prednisone, CP, RTX, IVIG, PEX
17	M	2016	91	84.7	0.1	224	23	APCC, TXA	Prednisone, CP
18	M	2016	75	66	5.9	5.4	18	APCC, TXA	Prednisone
19	F	2016	93	52	7.8	12	7	TXA	Prednisone
20	M	2017	73	55.9	4.3	3.2	13	TXA	Prednisone
21	F	2017	29	53	4.3	2.7	12	RFVIIa, TXA, Plasma derived FVIII, FFP	Prednisone
22	M	2018	91	101	0.2	22.4	17	RFVIIa, aPCC, TXA	Prednisone, CP
23	F	2018	84	97	0.1	9.6	54	RFVIIa, TXA	Prednisone, CP
24	M	2018	84	123	0.7	112	50	RFVIIa, TXA	Prednisone
25	F	2018	81	79	10	38	9	TXA	Prednisone
26	F	2018	60	119	0.1	52	28	APCC, TXA	Prednisone, CP

6									
27	M	2019	84	49	3.9	26	35	APCC, TXA	Prednisone, CP
28	F	2019	52	64	4	35	31	TXA	Prednisone
29	F	2019	45	52	4.3	16	10	TXA	Prednisone, CP
30	F	2020	88	56	10	25	19	TXA	Prednisone
31	F	2020	72	196	0.3	24	29	APCC, TXA	Prednisone, CP
32	M	2021	83	74	8	36	10	TXA	Prednisone, CP, IVIG
33	M	2021	78	140	4	35	8	APCC, TXA	Prednisone, CP
34	M	2022	76	125	1.2	35	30	APCC, TXA	Prednisone, CP
35	F	2022	46	145	4	38	60	RFVIIa, TXA	Prednisone, CP
36	M	2023	59	125	0.5	150	24	APCC, TXA	Prednisone, CP
37	F	2023	80	135	2	64	27	APCC, TXA	Prednisone, CP
38	M	2023	78	92	4.7	47	30	RFVIIa, TXA	Prednisone
39	M	2023	87	73	1	229	65	RFVIIa, TXA	Prednisone, CP, IVIG, MTX, PEX
40	F	2023	31	155	1	30	40	RFVIIa, TXA	Prednisone, CP
41	F	2023	46	75	4	15	30	APCC, TXA	Prednisone, CP

APCC: DD: Delay of Diagnosis. Activated Protrombin complex concentrates; RFVIIa: Activated Recombinant FVII; TXA: tranexamic acid; FFP: fresh frozen plasma; CP: cyclophosphamide; Csa: Cyclosporine; RXT: rituximab; PEX: plasma exchange; IVIG: Intravenous Immunoglobulin.




Figure 1. Number of patients diagnosed from 2005 to 2023 (n=41)




Figure 2. A simple drawing to remember how to suspect Acquired Haemophilia.